Restrictive organic mitral regurgitation associated with benfluorex therapy

European Journal of Echocardiography

Volumn 11, Issue 7, 2010, Pages 614-621

  Tribouilloy, Christophe ^a,b   Rusinaru, Dan ^a   Henon, Pierre ^a   Tribouilloy, Laurence ^a   Leleu, Franois ^a   Andréjak, Michel ^a,b   Sevestre, Henri ^a   Peltier, Marcel ^a   Caus, Thierry ^a,b  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

Drug induced valvular disease; Fibrotic valvular disease; Mitral regurgitation

Indexed keywords

BENFLUOREX; FENFLURAMINE;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN TISSUE; MALE; MITRAL VALVE REGURGITATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION;

AGED; APPETITE DEPRESSANTS; BODY MASS INDEX; CARDIOMYOPATHY, RESTRICTIVE; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FEMALE; FENFLURAMINE; HOSPITALS, UNIVERSITY; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; OBESITY; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 77955454397     PISSN: 15252167     EISSN: 15322114     Source Type: Journal    
DOI: 10.1093/ejechocard/jeq027     Document Type: Article

References (23)

1. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588
2. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000;283:1703-1709
3. Dahl CF, Allen MR, Urie PM, Hopkins PN. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med 2008;6:34.
4. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotoninergic medications. Circulation 2000;102:2836-2841
5. Zolkowska D, Baumann MH, Rothman RB. Chronic fenfluramine administration increases plasma serotonin (5-hydroxytryptamine) to non-toxic levels. J Pharmacol Exp Ther 2008;324:791-797
6. Sertola V, Dukat M, Glennon RA, Roth BL. Molecular determinants for the interaction of the valvulopathic anorexigen fenfluramine with the 5-HT2B receptor. Mol Pharmacol 2005;68:20-33.
7. Jian B, Xu J, Connolly J, Savani RC, Narula N, Liang B et al. Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta 1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 2002;161:2111-2121
8. Moulin P, Andre M, Alawi H, dos Santos LC, Khalid AK, Koev D et al. Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: an 18-week randomized double-blind study. Diabetes Care 2006;29:515-520
9. Noize P, Sauer M, Bruneval P, Moreau M, Pathak A, Bagheri H et al. Valvular heart disease in a patient taking benfluorex. Fundam Clin Pharmacol 2006;20: 577-578
10. Rafel Ribera J, Casanas Munoz R, Anguera Ferrando N, Batalla Sahun N, Castro Cels A, Pujadas Capmany R. Valvular heart disease associated with benfluorex. Rev Esp Cardiol 2003;56:215-216
11. Boutet K, Frachon I, Jobic Y, Gut-Gobert C, Leroyer C, Carlhant-Kowalski D et al. Fenfluramine-like cardiovascular side-effects of benfluorex. Eur Respir J 2009;33: 684-688
12. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 2005;352:875-883
13. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003;16:777-802.
14. DAgostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;12:2265-2281
15. Tribouilloy C, Lévy F, Rusinaru D, Guéret P, Petit-Eisenmann H, Baleynaud S et al. Outcome after aortic valve replacement for low flow/low gradient aortic stenosis without contractile reserve on dobutamine stress echocardiography. J Am Coll Cardiol 2009;53:1865-1873
16. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: A report from the American Society of Echocardiographys Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463
17. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6-9.
18. Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J. Drug-induced fibrotic valvular heart disease. Lancet 2009;374:577-585
19. Droogmans S, Kerkhove D, Cosyns B, Van Camp G. Role of echocardiography in toxic heart valvulopathy. Eur J Echocardiogr 2009;10:467-476
20. Weissman NJ, Tighe JF Jr, Gottdiener JS, Gwynne JT. As assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine or placebo. N Engl J Med 1998;339:725-732
21. Shively BK, Roldan CA, Gill EA, Najarian T, Loar SB. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999;100: 2161-2167
22. Burger AJ, Sherman HB, Charlamb MJ, Kim J, Asinas LA, Flickner SR et al. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. J Am Coll Cardiol 1999;34: 1153-1158
23. Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998;339:713-718